Please select an option below to help us tailor your newsletter to best suit your content interests!
A randomized, phase 2 study of the efficacy and tolerability of veliparib in combination with temozolomide or veliparib in combination with carboplatin and paclitaxel versus placebo plus carboplatin and paclitaxel in subjects with BRCA1 or BRCA2 mutation and metastatic breast cancer
Unresectable recurrent or metastatic disease
BRCA1 or BRCA2 germline mutation
ECOG 0-2
If HER2 positive, must have either progressed on HER2 tx or ineligible to receive HER2 tx
No more than 2 prior lines of cytotoxicchemotherapy
No prior taxane therapy in metastatic setting
No brain mets or history of brain mets
Not pregnant or breastfeeding_